GlassScriptPhysician profile
Daniel J Olson
NPI 1003234329
$20,405.29
in general payments reported to CMS, 2019-2025
10 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2022: $1,050 · 2023: $1,809 · 2024: $3,930 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Honoraria: $6,770 · Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,802.50 |
| Honoraria | $6,770.00 |
| Food and Beverage | $532.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iovance Biotherapeutics, INC. | $6,804.45 | 2025 | Amtagvi |
| Novartis Pharmaceuticals Corporation | $3,675.00 | 2022-2024 | |
| Immunocore Limited | $3,204.63 | 2025 | Kimmtrak |
| E.R. Squibb & Sons, L.L.C. | $2,880.00 | 2024 | |
| Springworks Therapeutics, INC. | $2,187.50 | 2025 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $1,170.00 | 2025 | Vimseltinib |
| Merck Sharp & Dohme LLC | $249.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.57 | 2023 | |
| Janssen Research & Development, LLC | $67.31 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.